Replimune Group (NASDAQ:REPL) Hits New 52-Week High - What's Next?

Key Points

• Replimune shares reached a new 52-week high of $15.83, up from a prior close of $14.71, giving the company a market capitalization of approximately $1.49 billion.
• Analyst sentiment is mixed but leans positive, with a consensus “Moderate Buy” rating from 10 analysts and a $11.86 average price target. Recent upgrades from Wedbush and BMO Capital Markets contrast with multiple sell ratings.
• The company reported a quarterly loss of $0.72 per share, missing expectations by $0.03, while insiders sold shares primarily to cover tax obligations. Institutional investors own a substantial 92.53% of the stock.

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report)'s stock price reached a new 52-week high on Tuesday . The stock traded as high as $15.83 and last traded at $15.8380, with a volume of 2126037 shares traded. The stock had previously closed at $14.71.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Wedbush upgraded shares of Replimune Group from a "neutral" rating to an "outperform" rating and set a $12.00 price target on the stock in a report on Friday, August 7th. Weiss Ratings cut shares of Replimune Group from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, August 11th. Cantor Fitzgerald restated an "overweight" rating on shares of Replimune Group in a research note on Wednesday, August 12th. Wall Street Zen raised shares of Replimune Group from a "strong sell" rating to a "sell" rating in a research report on Saturday, May 23rd. Finally, BMO Capital Markets raised shares of Replimune Group from an "underperform" rating to an "outperform" rating and set a $16.00 price target for the company in a research note on Tuesday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $11.86.

Replimune Group Price Performance

The company has a debt-to-equity ratio of 1.00, a current ratio of 5.23 and a quick ratio of 5.23. The firm has a fifty day moving average of $11.36 and a two-hundred day moving average of $8.11. The stock has a market capitalization of $1.49 billion, a P/E ratio of -5.03 and a beta of 0.88.

Replimune Group (NASDAQ:REPL - Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). On average, analysts predict that Replimune Group, Inc. will post -2.78 EPS for the current year.

Insider Activity at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 11,447 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $148,467.59. Following the sale, the insider owned 224,215 shares of the company's stock, valued at approximately $2,908,068.55. This trade represents a 4.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CAO Andrew Schwendenman sold 7,632 shares of the business's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total value of $98,987.04. Following the completion of the transaction, the chief accounting officer directly owned 99,425 shares of the company's stock, valued at approximately $1,289,542.25. The trade was a 7.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 91,124 shares of company stock valued at $1,149,244 over the last quarter. 5.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

A number of large investors have recently added to or reduced their stakes in REPL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Replimune Group by 17.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company's stock valued at $435,000 after buying an additional 6,653 shares in the last quarter. Millennium Management LLC raised its stake in shares of Replimune Group by 2.8% during the 1st quarter. Millennium Management LLC now owns 1,223,236 shares of the company's stock worth $11,927,000 after acquiring an additional 33,574 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Replimune Group by 20.9% during the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company's stock valued at $6,729,000 after acquiring an additional 119,145 shares during the last quarter. Rhumbline Advisers boosted its stake in Replimune Group by 6.9% in the second quarter. Rhumbline Advisers now owns 102,005 shares of the company's stock valued at $948,000 after acquiring an additional 6,616 shares in the last quarter. Finally, Sei Investments Co. boosted its stake in Replimune Group by 149.5% in the second quarter. Sei Investments Co. now owns 30,478 shares of the company's stock valued at $283,000 after acquiring an additional 18,263 shares in the last quarter. 92.53% of the stock is currently owned by institutional investors.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company's proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune's lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source